Fulvestrant: beside a new treatment under test
271 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 3. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerTerminatedNCT05176080Phase 1/2Report a problem
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerActive, not recruitingNCT05077449Phase 3Report a problem
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2Report a problem
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Phase 3Report a problem
- Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast CancerStatus unknownNCT05047848Not applicableReport a problem
- Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+GoserelinStatus unknownNCT05004142Phase 2Report a problem
- Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast CancerStatus unknownNCT04999540Phase 2Report a problem
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingNCT04920708Phase 2Report a problem
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3Report a problem
- Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerStatus unknownNCT04856371Phase 1Report a problem
- Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04851613Phase 3Report a problem
- A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerCompletedNCT04796623Phase 2Report a problem
- Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1Report a problem
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1Report a problem
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2Report a problem
- A Phase I/II Study of XZP-3287 in Metastasis Solid TumorsActive, not recruitingNCT04539496Phase 1/2Report a problem
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1Report a problem
- Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.CompletedNCT04483505Phase 1Report a problem
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2Report a problem
- A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerStatus unknownNCT04355520Phase 1/2Report a problem
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2Report a problem
- A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid TumorsCompletedNCT04247126Phase 1Report a problem
- Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast CancerActive, not recruitingNCT04115306Phase 1/2Report a problem
- Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive,HR-Positive Metastatic Breast CancerStatus unknownNCT04034589Phase 2Report a problem
- Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2Report a problem
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Active, not recruitingNCT03959891Phase 1Report a problem
- A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03927456Phase 3Report a problem
- Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2Report a problem
- A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerCompletedNCT03481998Phase 1/2Report a problem
- Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerTerminatedNCT03430466Phase 2Report a problem
- SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast CancerTerminatedNCT03386162Phase 2Report a problem
- AZD5363 in Patients With Advanced Solid Tumors Harboring AKT MutationsCompletedNCT03310541Phase 1Report a problem
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedNCT03308201Phase 1Report a problem
- Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1Report a problem
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2Report a problem
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2Report a problem
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2Report a problem
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2Report a problem
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2Report a problem
- A Study of SY-1365 in Adult Patients With Advanced Solid TumorsTerminatedNCT03134638Phase 1Report a problem
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1Report a problem
- G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownNCT02983071Phase 1/2Report a problem
- SFX-01 in the Treatment and Evaluation of Metastatic Breast CancerCompletedNCT02970682Phase 2Report a problem
- A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid TumorsCompletedNCT02792465Phase 1Report a problem
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerCompletedNCT02684032Phase 1Report a problem
- Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownNCT02626507Phase 1Report a problem
- Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1Report a problem
- To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCompletedNCT02549430Phase 2Report a problem
- PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedNCT02389842Phase 1Report a problem
- Phase I Study of the Combination of MLN9708 and FulvestrantTerminatedNCT02384746Phase 1Report a problem
- A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerCompletedNCT02333370Phase 1Report a problem
- Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursCompletedNCT02260661Phase 1Report a problem
- Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedNCT02219789Phase 1Report a problem
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedNCT02216786Phase 2Report a problem
- Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast CancerWithdrawnNCT02115594Phase 2Report a problem
- Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerCompletedNCT02088684Phase 1Report a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingNCT02057133Phase 1Report a problem
- Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerActive, not recruitingNCT01992952Phase 1/2Report a problem
- A Study of LY3023414 in Participants With Advanced CancerCompletedNCT01655225Phase 1Report a problem
- Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyCompletedNCT01437566Phase 2Report a problem
- MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT01344031Phase 1Report a problem
- BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerCompletedNCT01339442Phase 1Report a problem
- Study of AFP464 +/- Faslodex in ER + Breast CancerTerminatedNCT01233947Phase 2Report a problem
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedNCT01226316Phase 1Report a problem
- A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedNCT01219699Phase 1Report a problem
- Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor TherapyCompletedNCT01160718Phase 2Report a problem
- Trial of ZD6474 and Faslodex in Non-Small Cell Lung CancerWithdrawnNCT01004419Phase 1Report a problem
- Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast CancerCompletedNCT00811369Phase 2Report a problem
- Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast CancerTerminatedNCT00774878Phase 2Report a problem
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast CancerTerminatedNCT00206414Phase 2Report a problem
- Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer PatientsCompletedNCT00046371Phase 2Report a problem